EGFR and metastatic colorectal cancer: The response seen in this patient on erlotinib/cetuximab/bevacizumab may be due to synergistic effect of simultaneous EGFR and vascular endothelial growth factor (VEGF) inhibition, as demonstrated in preclinical models, including EGFR inhibitor-resistant cell lines[34] and in patients with metastatic colorectal cancer[35], and NSCLC[36, 37].